Furazolidone in Helicobacter pylori therapy: Misunderstood and often unfairly maligned drug told in a story of French bread

Saudi Journal of Gastroenterology

Volumn 18, Issue 1, 2012, Pages 1-2

  Graham, David ^a,b   Lu, Hong ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; EPHEDRINE; FURAZOLIDONE; METRONIDAZOLE; MONOAMINE OXIDASE INHIBITOR; PHENYLEPHRINE; PHENYLPROPANOLAMINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; BEAN; BEER; CARCINOGENICITY; CHEESE; CONSTIPATION; DRUG EFFICACY; DRUG MARKETING; DRUG TREATMENT FAILURE; EDITORIAL; ENTERITIS; FOOD AND DRUG ADMINISTRATION; GLYCYRRHIZA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LENTIL; MEAT; NONHUMAN; SOYBEAN; TERATOGENICITY; WINE;

ANTI-INFECTIVE AGENTS, LOCAL; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 84856448184     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.91724     Document Type: Editorial

References (9)

1. Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter 2011;16:343-5.
2. Graham DY, Rimbara E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol 2011;45:309-13.
3. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009;7:145-8.
4. Zullo A, Ierardi E, Hassan C, De Francesco V. Furazolidone-based therapies for Helicobacter pylori infection: A pooled-data analysis. Saudi J Gastroenterol 2012;18:11-7. (Pubitemid 46723156)
5. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Food Additives, Feed Additives and Naturally Occurring Substances Last updated: 16 Apr 1998. Geneva: WHO; 1983. p. 141.
6. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
7. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am 2010;39:465-80.
8. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
9. Graham DY, Klein PD, Opekun AR, Smith KE, Polasani RR, Evans DJ Jr, et al. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol 1989;84:233-8. (Pubitemid 19081677)